- Table of Contents
We validate the specificity of these antibodies to SLC34A2 by testing them on tissues known to express SLC34A2 positively and negatively. Browse below to find the SLC34A2 antibody that suites your experiment. We have 2 of these antibodies and many publications and validation images.
If you cannot find antibodies that fit your needs, contact us for making custom antibodies. We have a full suite of custom antibody services covering from research to diagnostic and therapeutic applications.
Facts about Sodium-dependent phosphate transport protein 2B.
May have a function in the synthesis of surfactant in lungs' alveoli. .
|SLC34A transporter family|
NAPI-3B; NPTIIb; sodium/phosphate cotransporter 2B; solute carrier family 34 (sodium phosphate), member 2; type II sodium-dependent phosphate transporter 3b
|Sequence:||4; NC_000004.12 (25655851..25678748)|
Highly expressed in lung. Also detected in pancreas, kidney, small intestine, ovary, testis, prostate and mammary gland. In lung, it is found in alveolar type II cells but not in bronchiolar epithelium.
Membrane; Multi-pass membrane protein.
If you're thinking about investing in Boster Bio's SLC34A2 peptide you may be wondering what its best uses are. This article will help answer this question. Here are the benefits of SLC34A2's peptides and how you can utilize them to your advantage. Continue reading to learn more. You'll be happy that you did.
The creation of vaccines and anti-tumor antibodies has become an increasingly important goal than traditional drug discovery in recent years. The SLC34A2 molecule isolates specific peptides which can be used to create anti-tumor antibodies. Antibodies against this target are beneficial for screening anti-tumor drugs. The present invention blends two methods to create an anti-tumor vaccine. One approach is to make a peptide using human or animal cells.
SLC34A2 proteins have either an active element or an enzyme. It is possible to detect the radioactive element by using any of the normal mutagenesis or counting methods. The isotope chosen could be 3H, 14C, 32P, 35S, the 131I or 186Re. These antibodies are effective in purifying mutant SLC34A2 proteins.
Alternately you can buy blocking peptides. The price of these peptides is dependent on the length of the immunogen and the antibody. They are available in various sizes and can be stored at -20°C for a year. The SLC34A2 peptide's cost can be purchased from Sanbio. It depends on the immunogen.
The SLC34A2 antibody made by the present invention contains DNA sequences from the SLC34A2 peptide. These peptides have an amino acid sequence SEQ ID NOS 1-8. They can be made from other molecules. Alternatively they can be made by using a hybridoma technique. Once the polyclonal antibody is created, it can be examined and used as a diagnostic tool.
The adjuvant formulation and SLC34A2 protein could be used in the near future for treatment of cancer. Patients with certain types or cancers can benefit from this novel cancer immunotherapy. In this manner, SLC34A2 peptide could be used to treat breast cancer, lung cancer, as well as uterine and gastrointestinal tumors. This immunotherapy treatment could be able to cure these cancers.
A pharmaceutical composition of the present invention contains at least two antibodies against SLC34A2 selected from SEQ ID NOS 1-8. It also includes a pharmaceutically acceptable carrier. This is a promising approach to research into cancer. The composition is available in a variety of forms, including ELISA as well as chimeric antibodies and various variants of antibody formulations. The antibodies can detect the protein with a sensitivity of just picograms.
Researchers at Boster Bio created the SLC34A2 protein. The human cDNA library has the code for this protein. The protein has 690 amino acids and is predicted to cross the membrane several times. It has eight transmembrane regions. It also has numerous functional subunits, including the sodium-dependent phosphate transport protein 2b.
One of the most important characteristics of SLC34A2 is its capacity to regulate the movement of the phosphate. It is a major target for immunotherapy against cancer. It is identified by antibodies that target the amino acids 312-340 of SLC34A2.
Boster Bio SLC34A2 RNAi peptides target a part of the sodium-dependent phosphate transporter protein 2b (NaPi2b). The molecule is comprised of amino acids 312-340 within its extracellular domain, making it an excellent target for screening and the development of therapeutic agents. These RNAi peptides have been validated by flow cytometry, IHC-P and IHC F assays. The antibodies are specifically designed to recognize mutant SLC34A2 as well as the related proteins.
Boster Bio's SLC34A2 peptide is bound to the protein. Each purified antibody has the SEQ ID NOS 1-8 and is made from an antibody that is polyclonal. Each antibody has an amino acid sequence corresponding to the peptide SLC34A2 and can also be covalently linked to other molecules.
In addition to their anti-tumor capabilities SLC34A2 proteins are effective in screening and producing antibodies against the growth factor receptor and SLC34A2. This is especially useful in the field of immunotherapy and cancer research since the majority of cancers are found in mammals. A related anti-tumor protein can be used to test for the presence of cancer cells.
The invention utilizes the protein SLC34A2 to screen potential compounds. The test compound is administered to an in vitro cell that is expressing SLC34A2 protein. The resultant culture can then be assessed to determine if the potential drug can alter SLC34A2 activity. The assay method can also be used to assess the efficacy of a drug currently in use, as compared to its capability to block the activity of SLC34A2.
Functional assays made using BBMVs from the kidneys of rats show that SLC34 proteins do not regulate Na+-coupled Pi transport capacity. Instead, the rest of the transport is controlled by the influence of the diet's control. The SLC34 proteins came from animals fed high or low-Pi diets, respectively. The amount of SLC34 proteins within membranes was affected by diet-related changes. Pi uptake is typically peaking around 1 minute.
The vaccines that contain SLC34A2 protein peptides can be administered intramuscularly, subcutaneously, or as an infusion. Peptides are generally produced as emulsions , or injectables. These peptides may be covalently bound to glycolipid analogs and may exhibit enhanced adjuvanting effects. They can also be used to treat papillary serous tumors.
Pharmaceutical compositions in accordance with the invention contain at least two antibodies to SLC34A2 proteins, that are chosen from SEQ ID NOS 1-8. They also comprise a clinically acceptable carrier. The peptides can also be used as an immunotherapy. These antibodies can also be used for patients suffering from autoimmune diseases. The therapeutic compositions may also be used for inflammatory diseases. In addition to SLC34A2-derived peptides, the pharmaceutical compositions may contain immunogenic peptides as well.
A recombinant, recombinant, antibody targeted against SLC34A2 and its amino acids 312-340 could be produced. Variable regin sequences or CDR regions could be included in the antibodies. They will increase their binding to antigens of tumors. The peptides in SLC34A2 are generated through a process of fermentation. The biotechnological process has provided a novel drug formulation.